scPharmaceuticals Receives $16M in Series A Funding
March 28, 2014
scPharmaceuticals, a developer of products for subcutaneous delivery (a delivery system suitable for patient self-administration), has closed a $16 million Series A financing round co-led by 5AM Ventures and Lundbeckfond Ventures. The proceeds will help further develop the company's first two pharmaceutical products and its associated drug delivery technology.
scPharmaceuticals' first product is a drug-device combination based on the active ingredient furosemide, an important component in heart failure treatment. The second product is a drug-device combination of a cephalosporin antibiotic, currently only available for intramuscular and intravenous administration. Both products aim to reduce the burden of disease for patients and offer a safer and more convenient form of treatment.